Gut resistome of NSCLC patients treated with immunotherapy

BackgroundThe newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 (Programmed Cell Death Ligand 1). PD-L1 is the only validated predictor factor for immunotherapy efficacy, but it...

全面介紹

書目詳細資料

Principais autores:	Ewelina Iwan, Anna Grenda, Arkadiusz Bomba, Katarzyna Bielińska, Dariusz Wasyl, Robert Kieszko, Anna Rolska-Kopińska, Izabela Chmielewska, Paweł Krawczyk, Kamila Rybczyńska-Tkaczyk, Małgorzata Olejnik, Janusz Milanowski
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2024-08-01
叢編:	Frontiers in Genetics
主題:	resistome microbiome NSCLC immunotherapy metagenomics
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fgene.2024.1378900/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!